<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463317</url>
  </required_header>
  <id_info>
    <org_study_id>CLOSURE-AF-DZHK16</org_study_id>
    <nct_id>NCT03463317</nct_id>
  </id_info>
  <brief_title>Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy</brief_title>
  <acronym>CLOSURE-AF</acronym>
  <official_title>Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stiftung Institut fuer Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study goal is to determine the clinical benefit of percutaneous catheter‐based left
      atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at
      high risk of stroke (CHA2DS2‐VASc Score ≥2) as well as high risk of bleeding as compared to
      best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The individualized therapy with oral anticoagulants is considered to be an essential
      preventive therapy in patients with atrial fibrillation. The risk of stroke can be reduced by
      approximately 65%. However, long-term anticoagulation therapy also increases the risk of
      major bleeding.

      A significant proportion of patients at high risk of stroke do not tolerate long-term
      anticoagulation due to various relative or absolute contraindications. As demonstrated in
      previous studies with non-vitamin K antagonist anticoagulants (NOAK), 20-25% of patients were
      unable to tolerate long-term anticoagulation therapy.

      For this reason, additional therapeutic approaches for stroke prevention in patients with
      atrial fibrillation have been developed.

      A promising approach is catheter-based closure of the left atrial appendage, because more
      than 90% of cardiac thrombi in patients with non-valvular atrial fibrillation are detected in
      the left atrial appendage. Recent registry studies show that the safety of LAA occluder
      implantation is promising. However, further scientific studies are required, in order to
      explore more benefits of the underlying method and eligible patients for implantation.

      Study objectives:

      The study goal is to determine the clinical benefit of percutaneous catheter‐based left
      atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at
      high risk of stroke (CHA2DS2‐VASc Score ≥2) as well as high risk of bleeding as compared to
      best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Event-driven group-sequential design, non-inferiority test, if significant followed by superiority test</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint (net clinical benefit)</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>Survival time free of the composite of:
Stroke (including ischemic or hemorrhagic stroke)
Systemic embolism
Major bleeding (BARC type 3‐5)
Cardiovascular or unexplained death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary endpoint events per year</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>assessed by the number of primary endpoint events during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint: MACCE</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>(stroke/systemic embolism/cardiovascular death/myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>(including all-cause death, cardiovascular death, non‐ cardiovascular death, peri‐procedural death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>BARC type 3‐5 (according to the BARC (Bleeding Academic Research Consortium) definition for bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>assessed by the rate of systemic embolism during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic/hemorrhagic stroke including transient ischemic attack</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>(TIA: defined as neurological deficit of vascular origin lasting ≤24 hours without corresponding brain lesion). Stroke and TIA will be assessed according to 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol, 2015.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>Myocardial infarction will be assessed according to the third universal definition of myocardial infarction (Eur Heart J, 2012).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for bleeding or cardiovascular event</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>Hospitalization for bleeding or cardiovascular event will be assessed according to 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol, 2015.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognitive function</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>assessed by MoCA (= Montreal Cognitive Assessment). The MoCA will be used to assess the cognition of patients. Minimum score: 0 points, maximum score: 30 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health-related quality of life</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>assessed by EQ-5D-5L (German Version 1.0). The EQ-5D-5L consists of a 5-question multi-attribute questionnaire and a visual analogue self-rating scale. Minimum score: 0, maximum score: 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related thrombus</measure>
    <time_frame>follow-up: 24 months</time_frame>
    <description>assessed by echocardiographic follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1512</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LAA closure group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical care group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CE-mark approved LAA closure devices</intervention_name>
    <description>LAA closure with post procedure treatment</description>
    <arm_group_label>LAA closure group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group</description>
    <arm_group_label>LAA closure group</arm_group_label>
    <other_name>ASS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group</description>
    <arm_group_label>LAA closure group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Patients allocated to the best medical care group receive either NOAC therapy or VKA</description>
    <arm_group_label>Best medical care group</arm_group_label>
    <other_name>Pradaxa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Patients allocated to the best medical care group receive either NOAC therapy or VKA</description>
    <arm_group_label>Best medical care group</arm_group_label>
    <other_name>Xarelto®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Patients allocated to the best medical care group receive either NOAC therapy or VKA</description>
    <arm_group_label>Best medical care group</arm_group_label>
    <other_name>Eliquis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Patients allocated to the best medical care group receive either NOAC therapy or VKA</description>
    <arm_group_label>Best medical care group</arm_group_label>
    <other_name>LIXIANA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenprocoumon</intervention_name>
    <description>Patients allocated to the best medical care group receive either NOAC therapy or VKA</description>
    <arm_group_label>Best medical care group</arm_group_label>
    <other_name>Marcumar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Patients allocated to the best medical care group receive either NOAC therapy or VKA</description>
    <arm_group_label>Best medical care group</arm_group_label>
    <other_name>Coumadin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  Documented atrial fibrillation (paroxysmal, persistent, long-standing persistent or
             permanent)

          -  CHA2DS2VASc-Score ≥ 2

          -  High risk of bleeding under oral anticoagulation or contraindication for (N)OAC
             therapy, in particular patients with at least one of the following conditions (a-e):

               1. HAS-BLED-Score ≥ 3

               2. Prior intracranial/intraspinal bleed, intraocular bleed compromising vision
                  (BARC: type 3c)

               3. Hemorrhagic/bleeding complication fulfilling BARC type 3a or 3b: gastrointestinal
                  tract, genitourinary tract or respiratory tract bleeding, where the patient is
                  considered to be at a persistently increased risk of bleeding, e.g. the cause of
                  bleeding cannot be successfully eliminated

               4. Chronic kidney disease with eGFR 15-29 ml/min/1.73 m2

               5. Any recurrent bleeding making chronic anticoagulation not feasible

          -  Subject eligible for an LAA occluder device

          -  Age ≥18 years

          -  Willing and capable of providing informed consent, participating in all associated
             study activities

        Key Exclusion Criteria:

          -  Absolute contraindication to acetylsalicylic acid

          -  Comorbidities other than AF requiring chronic (N)OAC therapy, e.g. mechanical heart
             valve prosthesis

          -  Symptomatic carotid disease (if not treated)

          -  Complex aortic atheroma with mobile plaque (Kronzon classification grade V)

          -  Heart transplant

          -  Active infection or active endocarditis or other infections resulting in bacteremia

          -  Cardiac tumor

          -  Severe liver failure (Child-Pugh class C or liver failure with coagulopathy)

          -  Severe renal failure (GFR &lt;15 ml/min/1.73m2)

          -  Pregnancy or breastfeeding

          -  For female patients of reproductive potential: Unwilling to agree to use a highly
             effective method of contraception (Pearl index &lt;1) throughout the study period

          -  Subject with participation in another interventional clinical trial during this study
             or within 30 days before entry into this trial.

          -  Known terminating disease with life expectancy &lt;1 year (including those with end-stage
             heart failure)

          -  Subjects, who are committed to an institution due to binding official or court order

          -  Subject who is dependent on the Site, the Site Investigator, any sub- investigator,
             his/her representative and/or the sponsor

          -  Persons who are not proficient in the German language

          -  Acute heart failure within the last 30 days

          -  Cardiac intervention within the last 30 days

          -  Subjects with planned cardiac or non-cardiac surgery or intervention. (These subject
             can be included 30 days after such intervention / surgery.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Landmesser, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes J Hartung, MD</last_name>
    <phone>+49 30 450 513 706</phone>
    <email>johannes-jakob.hartung@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vivantes Klinik Am Urban, Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, CBF, Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln, Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Berlin Köpenick, Klinik für Innere Medizin - Schwerpunkt Kardiologie und Angiologie</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, CVK, Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin, Innere Medizin - Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Brandenburg GmbH, Zentrum für Innere Medizin I</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gesundheit Nord gGmbH, Klinikum Links der Weser, Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe, Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katholisches Krankenhaus &quot;St. Johann Nepomuk&quot;, Klinik für Innere Medizin II - Kardiologie</name>
      <address>
        <city>Erfurt</city>
        <zip>99097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik II - Kardiologie und Angiologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universität Greifswald, Klinik für Innere Medizin B - Kardiologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Barmbek, I. Med. Abteilung - Kardiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford, Med. Klinik III/ Kardiologie</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH, Klinik für Innere Medizin II - Kardiologie</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UKSH - Campus Kiel, Medizinische Klinik III - Kardiologie, Angiologie, Intensivmedizin</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UKSH - Universitäres Herzzentrum Lübeck, Medizinische Klinik II - Kardiologie, Angiologie, Intensivmedizin</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, Kardiologie I - Zentrum für Kardiologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim, I. Medizinische Klinik - Kardiologie, Angiologie, Intensivmedizin</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München, Klinik an der TU München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LMU Universität München, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Osypka Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum München GmbH, Klinikum Neuperlach, Klinik für Kardiologie, Pneumologie, intern. Intensivmedizin</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm, Klinik für Innere Medizin II - Kardiologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun-Klinikum Zwickau, Klinik für Innere Medizin I - Kardiologie, Angiologie, Intern. Internsivmedizin</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://closure-af.dzhk.de/</url>
    <description>trial website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Ulf Landmesser</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Left atrial appendage closure</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

